Skip to main content
. 2021 Jun 29;11(7):618. doi: 10.3390/jpm11070618

Table 2.

Summary of molecular signatures incorporating IL6ST. The markers included in each model are listed, as well as its prognostic or predictive value. See Figure 2 and Figure 3 for further description of the hybrid multifactor signatures.

Original Publication Signature Biomarkers Incorporated in the Signature Clinical Significance
Filipits et al. (2011)
[44]		 EndoPredict Low risk-associated (surrogates for ER signalling/cell differentiation): RBBP8, IL6ST, AZGP1, MGP, STC2
  • -

    Stratifies into prognostic groups for risk of distant recurrence in ER+/HER2- BC patients

  • -

    Predictive for benefit from the addition of chemotherapy in the high-risk group in ER+/HER2- patients
High risk-associated (surrogates for proliferation/cell cycle): BIRC5, UBE2C, DHCR7
Housekeeper genes: CALM2, OAZ1, RPL37A
Control gene: HBB
EPclin Clinical factors: Lymph node status, tumour size
Molecular factors: EndoPredict genes
LR-associated:IL6ST (5 probes), NPY1R, ELOVL5, ASAH1 (2 probes), ALDH6A1, SYBU, RAB5C, PTP4A2, HSPA2, SLC7A8 ADRA2A, MYCBP, CX3CR1, ERCC1, DNAJA3, NINJ1, C4orf43, IFI35, ZNF688, SNX1, CREBL2, HPN, NME3, PDHB, NKX3-1, DEXI, GSTM3, LCMT1
Sota et al. (2014)
[49]		 IRSN-23 Non-pCR-associated: IL6ST (3 probes), CX3CR1, ZEB1 (2 probes), SEMA3C, HFE, EDA
  • -

    Stratifies into groups predictive for response to NAC.
pCR-associated: CARD9, IDO1, CXCL9, PNP, CXCL11 (2 probes), CEBPB, CD83, CD1D, CTSC, CXCL10, IGHG1, VEGFA, CR2
Turnbull et al. (2016)
[51]		 EER4 Pretreatment levels: IL6ST, NGFRAP1
  • -

    Predictive for response to AIs in postmenopausal ER+/HER2- BC patients.

  • -

    Prognostic for long term outcome (RFS and BCSS) in postmenopausal ER+/HER2- BC patients treated with AIs.
2-week levels: ASPM, MCM4
EA2 Pretreatment levels: IL6ST
  • -

    Prognostic for long term outcome (RFS and BCSS) in ER+/HER2- BC patients treated with ET, regardless of menopausal status.
2-week levels: MCM4
EA2clin Clinical factors Lymph node involvement, tumour size and tumour grade
  • -

    Prognostic for long term outcome (RFS and BCSS) in ER+/HER2- BC patients treated with ET, regardless of ET regimen.
Molecular factors Pretreament level: IL6ST
2-week level: MCM4
Tsunashima et al. (2018)
[54]		 42GC NLR-associated: KLF7, STS, RALA, SMURF2, OXTR, ABCC10, ASAP2, CALB2, OPA1
  • -

    Stratifies into prognostic groups for risk of early and late recurrence in ER+ BC.
LR-associated: IL6ST (5 probes), NPY1R, ELOVL5, ASAH1 (2 probes), ALDH6A1, SYBU, RAB5C, PTP4A2, HSPA2, SLC7A8 ADRA2A, MYCBP, CX3CR1, ERCC1, DNAJA3, NINJ1, C4orf43, IFI35, ZNF688, SNX1, CREBL2, HPN, NME3, PDHB, NKX3-1, DEXI, GSTM3, LCMT1

42GC, 42-gene classifier; AI, aromatase inhibitor; BC, breast cancer; BCSS, BC-specific survival; EA2, EndoAdjuvant 2; EA2clin, EndoAdjuvant 2 clinical; EER4, Edinburgh EndoResponse 4; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; EA2, EndoAdjuvant2; EA2clin, EndoAdjuvant2 clinical; ET, endocrine therapy; IRSN-23, immune-related 23-gene signature for NAC; NAC, neoadjuvant chemotherapy; pCR, pathological complete response; RFS, recurrence-free survival.